Infliximab Now Approved for Use in Psoriatic Arthritis
Infliximab (Remicade®), currently an approved treatment for rheumatoid arthritis and Chron’s disease, is now FDA approved for reducing signs and symptoms of active arthritis in patients with psoriatic...
View ArticleEfficacy of Adalimumab in Patients with Active Psoriatic Arthritis
Both etanercept (Enbrel) and infliximab (Remicade) have been shown to be effective in the treatment of psoriasis and psoriatic arthritis in randomized, double-blind, placebo-controlled trials. Here...
View ArticleClik here to view.
New Onset Psoriatic Arthritis Reported in Psoriasis Patients Treated with...
The T-cell inhibitor efalizumab (Raptiva) has demonstrated efficacy in the treatment of moderate to severe plaque psoriasis. However, it has not demonstrated efficacy for the treatment of psoriatic...
View ArticleClik here to view.
Ustekinumab, an Inhibitor of IL 12/23, Studied in Patients with Psoriatic...
Arthritis Mutilans in a Patient with Psoriatic Arthritis There are currently no biologic treatment options available for patients with psoriatic arthritis (PsA) who are non-responsive to traditional...
View ArticleClik here to view.
Arthritis News: Golimumab Receives FDA Approval
FDA Approval for golimumab (which will by marketed under the trade name Simponi) was granted this week by the U.S. Food and Drug Administration. The drug received approval for the treatment of...
View ArticleClik here to view.
Study Explores the Prevalence of Psoriatic Arthritis Among Individuals with...
Estimates of the prevalence of psoriatic arthritis among individuals with skin psoriasis have varied in the literature from between 2% to more than 40%, depending on the method of ascertainment and...
View ArticleClik here to view.
Challenges in Screening for Latent TB in Inflammatory Arthritis
TNFα inhibitors have demonstrated great efficacy for the treatment of rheumatoid arthritis (RA). However, they are not without potential side effects with one being the reactivation of latent...
View ArticleCertolizumab pegol gains FDA approval for PsA and AS
Certolizumab pegol (Cimzia®) gained FDA approval in September/October 2013 for two new indications, adults with active psoriatic arthritis (PsA) and adults with active ankylosing spondylitis (AS)....
View ArticleApremilast (Otezla) approved by FDA
Apremilast (Otezla®) received FDA approval on March 21, 2014 for the treatment of adults with active psoriatic arthritis (PsA). It is the first oral medication in the U.S. with an approved indication...
View Article